Wednesday, May 27, 9 am PST, 10 am MST, 11 CST, Noon EST
Call In by Phone to Listen Live: (347) 637-2631 or Listen Live Via Computer
CAR T cells are a hot topic in multiple myeloma as an extremely powerful and potentially curative therapy. It is a highly personalized treatment because the patient’s own T-cells are redirected to eliminate cancerous cells using a targeted protein found on the myeloma cells. Learn what Dr. Hermann Einsele, MD and Dr. Michael Hudecek, MD are doing with CAR T cells to target the CS1 protein, commonly found on myeloma cells.
Hermann Einsele, MD, is Professor of Internal Medicine and Director of the Department of Internal Medicine at the University of Würzburg in Germany. Following his medical training at the Universities of Tubingen, Manchester, London and Seattle, he became a research fellow in the Department of Hematology/Oncology/Rheumatology/Immunology at the University of Tubingen, Germany. He was board certified in internal medicine in 1991 and became Assistant Professor in 1992. In 1996, he was board certified in hematology/oncology. He is a Visiting Professor at the Fred-Hutchinson-Cancer-Research-Center in Seattle, USA and the City of Hope Hospital, Duarte, USA.
Professor Einsele is a member of the American Society of Hematology, the European Group for Blood and Marrow Transplantation (EBMT), and the EBMT working parties for Infectious Disease and Immunobiology. He is currently a member of the board of the German Society of Blood and Marrow Stem Cell Transplantation. In 1999, he became Chairman of the German Study Group Multiple Myeloma. In 2003, he received the van Bekkum-Award of the European Society of Blood and Marrow Transplantation. He has published > 350 articles in peer-reviewed journals. His research interests include multiple myeloma, stem cell transplantation and adoptive immunotherapy. He is a member of the board of the German Lymphoma Group. In April 2011 he was elected Honorary Fellowship of the Royal College of Pathologists (London).
Dr. Michael Hudecek, MD, leads the CAR T cell lab work at the University ofWürzburg. Dr. Hudecek obtained his MD with summa cum laude from the University of Leipzig, Germany, and performed his post-doctoral research fellowship at the Fred Hutchinson Cancer Research Center in Seattle, WA, USA. Dr. Hudecek joined the University of Würzburg in 2012 as a clinical fellow and research group leader.